NOX OPEN BRIEFING CORPORATE PRESENTATION

Sydney, 6 December 2017: Noxopharm (ASX: NOX) and its US subsidiary, Nyrada Inc, are pleased to release their respective corporate presentations to be delivered today to an Open Briefing for shareholders and investors.

The Briefing will review:
- the Noxopharm clinical trial program for NOX66
- the anticipated key milestones for NOX66
- the Nyrada, Inc strategy.

Details of the Open Briefing are as follows:
Time: 12.30 pm – 1.30 pm
Venue: Level 41, 259 George St Sydney

About Noxopharm
Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

About Nyrada Inc.
Nyrada Inc is a US biotechnology company, established as a subsidiary of Noxopharm to focus on non-oncology drug development. Nyrada has 3 drug assets: NYX-104 (excitotoxicity inhibitor), NYX-205 (anti-inflammatory), NYX-330 (PCSK9 inhibitor).

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

www.noxopharm.com

Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.
ONCOLOGY
NOX66  Idronoxil (lipophilic form)
Multiple anti-cancer actions

1. Inhibits DNA repair
   (inhibits PARP-1, topoisomerases 1 and 2)

2. Promotes anti-tumour immunity
   (increases NK (natural killer) cell activity)
Oral Idronoxil

- Excreted quickly (45 min)
- Does NOT cross BBB

NOX66

- Excreted slowly (10 hours)
- Crosses BBB
DARRT

Direct and Abscopal Response to Radio-Therapy
Limitation of radiotherapy

*Metastatic cancer too extensive for radiation*
Radiotherapy applied to large tumours for pain relief

Shrinkage of irradiated tumours

DIRECT Response to Radio-Therapy

Noxopharm
DIRECT Response to Radio-Therapy

Radiotherapy applied to large tumours for pain relief

Shrinkage of irradiated tumours

Seeking complete remission of irradiated tumours
ABSCOPAL Response to Radio-Therapy

Exposed tumours respond

Non-exposed tumours also respond

Low-dose radiotherapy

Seeking complete remission of irradiated tumours

Abscopal response
**Features of an abscopal response**

- **Rare**
  - very rare phenomenon
- **Complete**
  - primary AND secondary tumours respond
- **Durable**
  - potentially permanent
- **Unrestricted**
  - range of cancers reportedly involved
- **Short treatment**
  - single course of treatment (7-14 days)
- **Low toxicity**
  - low-grade radiation sickness
DARRT

Direct Effect

- Patients with multiple (>3) tumours
- Irradiate 1-2 tumours (5 days)
- NOX66 14 days
- Scan + 2 months and 4 months

Abscopal Effect
Direct Effect

- Prostate cancer (metastatic castrate-resistant)
- Solid common cancers (eg. lung, breast, melanoma)
- Rare cancers (eg. sarcomas)

Abscopal Effect
Direct Effect

- $^{177}$ Lutetium-PSMA-617
- 4 x monthly intravenous injections of LuPSMA/10 days NOX66
- Prostate cancer (metastatic castrate-resistant)

Abscopal Effect

DARRT

Noxopharm
Where NOX66 + Radiotherapy needs a boost ..........

NOX66-001 Phase 1b Study Georgia

+ Low-dose carboplatin (AUC4 – monthly)

400 mg NOX66

5 patients: 1 progressive; 4 non-progressive

800 mg NOX66

7 patients: 1 progressive; 5 non-progressive; 1 partial response
What will a ‘good response’ look like?

- Lung Cancer trial (582 patients evaluated)
- Opdivo vs standard chemotherapy
  - Survival of 50% of patients - 12.2 months vs 9.4 months
  - Time to disease progression – 2.3 months vs 4.2 months
  - Overall Response Rate – 19% vs 12%
    - Four Complete Responses vs One
  - Adverse Reactions (>20% of patients) - fatigue, musculoskeletal pain, cough, breathing difficulty, decreased appetite

- US$150,000 treatment cost
- Sales for first 6 months 2016 = US$1.6 billion

http://www.opdivohcp.com/metastatic-nsclc/efficacy/clinical-trial-results
Moving towards first registration

Target Indication: NOX66 in combination with Radiotherapy for the treatment of patients with metastatic cancer

Studies:
- NOX66-002A: Determine Dose of NOX66 (Prostate Cancer)
- NOX66-006: Open Label, all tumours. Safety and efficacy
- NOX66-007: Randomised, 2-3 tumours. Efficacy in comparison to standard care
- LuPIN Study: $^{177}$Lu-PSMA and NOX66 (Prostate Cancer): Supporting registration
- Expansion of $^{177}$Lu-PSMA research
- Other Radiotherapy Research (supportive data, for expanded indication in future) – e.g. brain, paediatrics, stereotactic, brachytherapy etc.

Notes:
- Different Global Regulators may modify indication for specific tumour types
- Indication may also list when treatment can be used
- Indication will discuss how to use Radiotherapy with NOX66
- Rare cancers may not be included in indication, however evidence is important
- Reimbursement is as important as Registration
Beyond the trials to reach registration

- **Manufacturing and formulation**: Optimise NOX66 formulation; GMP Manufacturing

- **Pre-clinical / non-clinical**: *in vitro* and animal studies to meet regulatory and other requirements for registration and marketing

- **Medical Affairs**: Liaison with oncologists, advisory boards, congress attendance and presentation

- **Marketing**: Develop Noxopharm presence, brand-naming, commercialization (including pricing) strategy
Communicating Trials Progress 2018

• Progress – based on Data Safety Monitoring Committee Review
  • Independent body – researchers and statisticians
  • Regular meetings during trials – expect ~6 across trials in 2018
  • Review overall progress → decisions on continuation
  • Findings of DSMBs will be communicated

• Trial Data at conferences
  • Contingent on significant milestones in trials (end of study, all patients through a pre-defined time point) – expect ~4 in 2018
  • Requires considerable planning (e.g. ASCO – meeting June, submit presentation in February)
  • Requirement that data are embargoed until presented
  • Where significant outcomes, top line result may be released as per ASX requirements prior to conference
2 technologies

LIPROSE

P-PDT

3 drugs

NYX-104

NYX-205

NYX-330

3 indications

- Stroke
- Concussion
- Severe epilepsy

- Peripheral neuropathy

- Hypercholesterolaemia
NYX-104 Inhibitor of excitotoxicity

Excitotoxicity

stroke

epilepsy

head trauma

concussion
Receptors activated by small amount of glutamate. Small amount of Ca\textsuperscript{++} allowed to enter neuron, activating a series of events that leads to generation of an electrical signal.
NYX-104

**Excitotoxicity**

Size of original area of damage from stroke or concussion

Days to weeks later, excitotoxicity has increased area of damage up to **10-times**
1. **University of NSW Translational Neuroscience Facility:**
   Breakthrough identification of key protein promoting excitotoxicity *(TrpC3 isotope)*

2. **In vitro** screen of NOX compounds:
   **NYX-104** inhibits TrpC3

3. **Mouse model of human stroke:**
   **NYX-104** is potent inhibitor of excitotoxicity.
   70% reduction in area of brain death post-stroke.
NYX-205

Anti-inflammatory
Designed to cross the blood-nerve barrier

- Diabetes
- Alcoholism
- Peripheral neuropathy
- Chemotherapy
- Shingles
- Diabetes
- Alcoholism
- Peripheral neuropathy
- Chemotherapy
- Shingles
Peripheral neuropathy

Incidence in US estimated at 20 million:
- Diabetes
- Alcohol abuse
- Chemotherapy

Blood-nerve barrier is major obstacle to effective treatment. NYX-205 designed to cross this barrier.
Targeting peripheral neuropathy in cancer patients receiving chemotherapy

- 60% incidence at 3 months
- 30% incidence at 6 months

Currently no effective treatment
NYX-330

Hypercholesterolemia

High blood LDL

- Stroke
- Heart disease
- Hypertension
- Alzheimer’s
• **PCSK9** identified as superior drug target compared to statin drugs for lowering blood LDL levels.
• **PCSK9** is plasma protein that binds to the LDL-LDL receptor complex, preventing recycling of the LDL receptor and thereby increasing LDL levels.

**PCSK9** declared an unsuitable target for small molecule drug. Amgen develops monoclonal antibody. **Repatha** comes to market in 2015.
NYX-330

Hypercholesterolemia

Suitable binding site identified on PCSK9 for attachment of small molecule.

NYX-330 blocks binding of PCSK9 to LDL- LDL receptor complex.
- US-registered
- Focus on small molecules, non-oncology
- 67% owned by NOX; 33% Altnia Holdings
- Currently public unlisted; proposed US listing in 12-18 months
OFFER:

- Raise = AUD$6,000,000

- Seed capital = 1,500,000 New Shares (A$4 each; 2 Options per 3 Shares)

- Capital structure post-exercise of Options
  - NOX 50%
  - Altnia 25%
  - Seed investors 25%

Application for Shares by sophisticated investors, non-US residents only. Information Memorandum available: info@nyrada.com
Disclaimer

• This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

• This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

• This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

• Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

• Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.